Pemanfaatan Kulit Udang Untuk Pembuatan Kitosan Dan Glukosamin

Shrimp shells as side product of frozen shrimp industry isnot yet used in pharmaceutical or chemical industries. Shrimpshells has a chemical constituent called chitin, calcium carbonateand protein as main compounds. By decalcination in dilute aqueosHCl solution (1-2 N) and deproteination ill dilute aqueos NaOHsolution (3-4 Nj gives a chitin. Deacetylation of chitin in theexcess of aqueous 50 % NaOH solution produces chitosan. Inthe preleminary experiment indicated that water (< 10%) andash (< 2%) content of chit os an same as standard. Based on theexperiment result the optimum condition was obtained as 1N HCIsolution (1: 10), 3N NaOH solution (1:6) and 50 % NaOH solution(1: 5) resulted 12,61 % chitosan with deacetylation degree valueabout 70 % with FT1R methode. Hydrolysis of chitin or chitosanin excess HCl gives glucosamine about 17 %, it's a mixture of aand B-glucosa11line. Glucoseamine is identified using 1H and13C NMR spectrum

Letter to the Editor: Interventricular septum hydatid cyst presenting with acute lower limb ischemia: a case report

Cardiac hydatid cysts are rarely seen. The presentation of an acute lower limb ischemia secondary to embolization from an interventricular hydatic cyst is also rare. We describe a case of a 30-year-old-man who presented with acute lower limb ischemia revealing hydatid cyst of the interventricular septum and septal defect, and who was operated on successfully.Keywords: hydatidosis; embolism; interventricular septum; embolectomy; cardiopulmonary bypas

Perinatal and infant outcome in prenatally diagnosed hyperechogenic kidneys

Objective: Hyperechogenic kidneys are a relatively rare antenatal finding, which can generate significant parental anxiety due to uncertain prognosis. We report on the perinatal and infant outcomes of a large cohort of fetuses with antenatally diagnosed hyperechogenic kidneys. Methods: This was a retrospective analysis of all cases diagnosed prenatally with hyperechogenic kidneys between 2002 and 2017 in a large tertiary fetal medicine unit. Hyperechogenicity was defined as kidney parenchyma with greater echogenicity than that of the liver. Pregnancy, pathological and postnatal outcomes were collected from hospital and general practitioner records up to 1 year of age. Abnormal renal outcome was defined as elevated creatinine beyond 6 months of age, hypertension requiring medication or major kidney surgery, such as nephrectomy. Severe abnormal renal outcome was defined as the need for dialysis or kidney transplant at any stage. Results: Three-hundred and sixteen fetuses with hyperechogenic kidneys were identified at a mean gestational age of 21 (range, 13–37) weeks. The majority of cases (97%) had bilateral hyperechogenic kidneys. In the 265 cases with available follow-up data, other associated renal tract abnormalities were identified prenatally in 36%, concomitant extrarenal structural abnormalities in 39% and abnormal karyotype in 15% of cases. Of the 316 included cases, 139 did not survive, including 105 terminations of pregnancy, five intrauterine deaths and 29 early neonatal deaths. Only 4.3% (6/139) of these fetuses had isolated hyperechogenic kidneys while 28.1% (39/139) had associated multiple renal tract abnormalities alongside hyperechogenic kidneys and over two-thirds (67.6%; 94/139) had concomitant extrarenal abnormalities. Of the 177 cases that survived beyond 1 month of age, outcome data were available in 126. Of these, based on the antenatal findings, 60 (47.6%) cases had isolated hyperechogenic kidneys, 56 (44.4%) had associated renal structural abnormalities and 10 (7.9%) had additional extrarenal abnormalities. Considering renal outcome alone, kidney function was abnormal in 13 (21.7%), 10 (17.9%) and 0 (0%) infants in these three groups, respectively, although concurrent pathology clearly affected global outcome in the more complex cases. Neonatal mortality of 1.6% was observed in the isolated renal hyperechogenicity group. The presence of oligohydramnios or abnormal renal volume was not associated significantly with abnormal renal function (odds ratio (OR), 2.32 (99% CI, 0.54–10.02) and OR, 0.74 (99% CI, 0.21–2.59), respectively) in this group. Conclusions: Hyperechogenic kidneys are often complicated by associated renal tract and extrarenal abnormalities, aberrant karyotype and genetic disease, and these factors have a greater effect on overall outcome than does kidney echogenicity. The renal outcome of fetuses with isolated hyperechogenic kidneys is good generally, with over 70% of cases having normal renal function postpartum. Importantly, for prognostic counseling, all of the fetuses in this non-selected series with isolated hyperechogenic kidneys and normal amniotic fluid levels had normal renal outcome in infancy. © 2020 The Authors. Ultrasound in Obstetrics & Gynecology published by John Wiley & Sons Ltd on behalf of International Society of Ultrasound in Obstetrics and Gynecology

Effect of laser surface modification on SS316L surface roughness and laser heating temperature

Nowadays, stainless steel is widely used in laser processing applications, including laser heating, laser brazing, and laser welding. However, it has poor optical properties due to low laser energy absorption. However, this could be improved with the aid of laser surface modification (LSM). The significance of this work is to examine the influence of LSM laser power on the surface roughness of 316L stainless steel samples. First, the LSM laser power was varied from 15 to 27 W. Then, the surface topography and variation of the surface roughness values were examined by using a 3D optical microscope. Furthermore, the modified surface by LSM will be heated using laser radiation in order to analyze the effect of surface roughness towards laser heating temperature. The result revealed that as the LSM power increased, thereby resulting in an increase of surface roughness. The highest LSM laser power (27 W) produced the highest surface roughness with 28.98 μm. Experimental results illustrate that the heating temperature were increased 36%, corresponding to a polished flat reference surface, which indicates the increment in energy absorptivity

Microstructural Changes in Human Ingestive Behavior After Roux-en-Y Gastric Bypass During Liquid Meals

BACKGROUND. Roux-en-Y gastric bypass (RYGB) decreases energy intake and is, therefore, an effective treatment of obesity. The behavioral bases of the decreased calorie intake remain to be elucidated. We applied the methodology of microstructural analysis of meal intake to establish the behavioral features of ingestion in an effort to discern the various controls of feeding as a function of RYGB. METHODS. The ingestive microstructure of a standardized liquid meal in a cohort of 11 RYGB patients, in 10 patients with obesity, and in 10 healthy-weight adults was prospectively assessed from baseline to 1 year with a custom-designed drinkometer. Statistics were performed on log-transformed ratios of change from baseline so that each participant served as their own control, and proportional increases and decreases were numerically symmetrical. Data-driven (3 seconds) and additional burst pause criteria (1 and 5 seconds) were used. RESULTS. At baseline, the mean meal size (909.2 versus 557.6 kCal), burst size (28.8 versus 17.6 mL), and meal duration (433 versus 381 seconds) differed between RYGB patients and healthy-weight controls, whereas suck volume (5.2 versus 4.6 mL) and number of bursts (19.7 versus 20.1) were comparable. At 1 year, the ingestive differences between the RYGB and healthy-weight groups disappeared due to significantly decreased burst size (P = 0.008) and meal duration (P = 0.034) after RYGB. The first-minute intake also decreased after RYGB (P = 0.022). CONCLUSION. RYGB induced dynamic changes in ingestive behavior over the first postoperative year. While the eating pattern of controls remained stable, RYGB patients reduced their meal size by decreasing burst size and meal duration, suggesting that increased postingestive sensibility may mediate postbariatric ingestive behavior. TRIAL REGISTRATION. NCT03747445; https://clinicaltrials.gov/ct2/show/NCT03747445. FUNDING. This work was supported by the University of Zurich, the Swiss National Fund (32003B_182309), and the Olga Mayenfisch Foundation. Bálint File was supported by the Hungarian Brain Research Program Grant (grant no. 2017-1.2.1-NKP-2017-00002)

Non-communicable diseases among Orang Asli of Kampung Ulu Tual

Introduction: Non communicable disease is increasing in trend and becoming one of significant major global problem that involves all strata of population including the aborigines. In fact, the prevalence might be higher in this population due to lack of access for regular screening and different sociodemographic background including tendency to migrate in different areas. Methodology: This study aims to identify the prevalence of non-communicable diseases among adult population of Orang Asli in the remote area of Pahang. A cross sectional study was conducted on 20th April 2019 during community service in Kampung Ulu Tual, whereby communicable diseases had been screened. SPSS version 23 is used for statistical analysis. Associations between variables were measured. Results: Prevalence of overweight/obesity is 36.6%, hypertension is 3.3% and abnormal blood sugar is 53.3%. There is no statistical significant association between prevalence of the non-communicable diseases across age and gender. Discussion: The prevalence of overweight/obesity among Orang Asli in this region is almost similar in our national prevalence with more than half of them are prone to develop diabetes. This study proved a linear relationship between overweight/obesity, abdominal obesity and diabetes. Conclusion: These results highlight the need for urgent interventions to reduce and prevent risk factors of non-communicable diseases even in rural area of Pahan

Consumer perceptions of co-branding alliances: Organizational dissimilarity signals and brand fit

This study explores how consumers evaluate co-branding alliances between dissimilar partner firms. Customers are well aware that different firms are behind a co-branded product and observe the partner firms’ characteristics. Drawing on signaling theory, we assert that consumers use organizational characteristics as signals in their assessment of brand fit and for their purchasing decisions. Some organizational signals are beyond the control of the co-branding partners or at least they cannot alter them on short notice. We use a quasi-experimental design and test how co-branding partner dissimilarity affects brand fit perception. The results show that co-branding partner dissimilarity in terms of firm size, industry scope, and country-of-origin image negatively affects brand fit perception. Firm age dissimilarity does not exert significant influence. Because brand fit generally fosters a benevolent consumer attitude towards a co-branding alliance, the findings suggest that high partner dissimilarity may reduce overall co-branding alliance performance

Decision making in interhospital transport of critically ill patients: national questionnaire survey among critical care physicians

Objective: This study assessed the relative importance of clinical and transport-related factors in physicians' decision-making regarding the interhospital transport of critically ill patients. Methods: The medical heads of all 95 ICUs in The Netherlands were surveyed with a questionnaire using 16 case vignettes to evaluate preferences for transportability; 78 physicians (82%) participated. The vignettes varied in eight factors with regard to severity of illness and transport conditions. Their relative weights were calculated for each level of the factors by conjoint analysis and expressed in beta. The reference value (beta = 0) was defined as the optimal conditions for critical care transport; a negative beta indicated preference against transportability. Results: The type of escorting personnel (paramedic only: beta = 3.1) and transport facilities (standard ambulance beta = 1.21) had the greatest negative effect on preference for transportability. Determinants reflecting severity of illness were of relative minor importance (dose of noradrenaline beta = 0.6, arterial oxygenation beta = 0.8, level of peep beta = 0.6). Age, cardiac arrhythmia, and the indication for transport had no significant effect. Conclusions: Escorting personnel and transport facilities in interhospital transport were considered as most important by intensive care physicians in determining transportability. When these factors are optimal, even severely critically ill patients are considered able to undergo transport. Further clinical research should tailor transport conditions to optimize the use of expensive resources in those inevitable road trip

The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis

Idiopathic pulmonary fibrosis (IPF) is a progressive disease that usually affects elderly people. It has a poor prognosis and there are limited therapies. Since epigenetic alterations are associated with IPF, histone deacetylase (HDAC) inhibitors offer a novel therapeutic strategy to address the unmet medical need. This study investigated the potential of romidepsin, an FDA-approved HDAC inhibitor, as an anti-fibrotic treatment and evaluated biomarkers of target engagement that may have utility in future clinical trials. The anti-fibrotic effects of romidepsin were evaluated both in vitro and in vivo together with any harmful effect on alveolar type II cells (ATII). Bronchoalveolar lavage fluid (BALF) from IPF or control donors was analyzed for the presence of lysyl oxidase (LOX). In parallel with an increase in histone acetylation, romidepsin potently inhibited fibroblast proliferation, myofibroblast differentiation and LOX expression. ATII cell numbers and their lamellar bodies were unaffected. In vivo, romidepsin inhibited bleomycin-induced pulmonary fibrosis in association with suppression of LOX expression. LOX was significantly elevated in BALF of IPF patients compared to controls. These data show the anti-fibrotic effects of romidepsin, supporting its potential use as novel treatment for IPF with LOX as a companion biomarker for evaluation of early on-target effects